• Follow
  • Follow
  • Follow
  • Home
  • About
  • Science
    • ALS
    • Parkinson’s Disease
  • Mitometin
    • Pipeline
  • News
  • Investors
  • Publications
  • Contact
  • Follow
  • Follow
  • Follow
  • Home
  • About
  • Science
    • ALS
    • Parkinson’s Disease
  • Mitometin
    • Pipeline
  • News
  • Investors
  • Publications
  • Contact
Meet 2N Pharma at the Anglonordic Life Science Conference

Meet 2N Pharma at the Anglonordic Life Science Conference

by Nicole Overmars | May 3, 2022 | Press Releases

Aalborg – We are pleased to announce that Preben Bruun Nyzell has been invited to the Anglonordic Life Science Conference that takes place in London on May 4-5.   About Anglonordic The Anglonordic Life Science Conference is an investment and partnering...
US Department of Defense awarded 2N Pharma a grant of 944.000 USD

US Department of Defense awarded 2N Pharma a grant of 944.000 USD

by Nicole Overmars | Apr 12, 2022 | Press Releases

Aalborg – US Department of Defense has awarded 2N Pharma a grant of 944.000 USD. 2N Pharma is thrilled to announce that the US Department of Defense has awarded 2N Pharma a grant of 944.000 USD. We are extremely grateful for the financial support that will...
DKBIO 2022 brings together Scandinavian bioscience start-ups with investors

DKBIO 2022 brings together Scandinavian bioscience start-ups with investors

by Nicole Overmars | Apr 5, 2022 | Press Releases

Boston – We are thrilled to announce that Preben Bruun-Nyzell and John Nieland will attend DKBIO 2022 in Boston on April 6-7. About DKBIO Innovation Centre Denmark and the Danish Ministry of Foreign Affairs are hosting DKBIO 2022. One of our investors,...
Neurodegeneration: unique and innovative approach to develop a cure

Neurodegeneration: unique and innovative approach to develop a cure

by Nicole Overmars | Mar 24, 2022 | Press Releases

2N Pharma has big ambitions. Our mission is to do what no one has yet managed: develop effective drugs with our innovative approach for the neurological diseases ALS and Parkinson’s.    Unmet medical need Parkinson’s disease was first described...
Women in STEM: this is why a career in science is so fascinating

Women in STEM: this is why a career in science is so fascinating

by Nicole Overmars | Feb 11, 2022 | Press Releases

On the occasion of today’s International Day of Women and Girls in Science, we spoke with Angelique Corthals, an inspiring woman in STEM. She is a multifaceted scientist, and has years of experience in the fields of metabolic dysfunction and neurological...
« Older Entries

Recent Posts

  • Poster Presentation at the 4th ALS Drug Discovery Summit
  • Matthias Wulf
  • 3rd ALS Drug Discovery Summit
  • New article in npj Parkinson’s Disease
  • 2N Pharma and our CSO mentioned in the Washington Post

Recent Comments

    2npharma

    2N Pharma is a small biotech company with a big vision: we want to cure ALS and other currently incurable neurodegenerative diseases.

    2N Pharma
    We are thrilled with today's publication of an art We are thrilled with today's publication of an article (in Danish) in Dansk Biotek and BusinessReview in which we discuss our innovative approach to treating #parkinsonsdisease and #ALS. Read full text here: https://lnkd.in/ejqXRqeR
    Today marks the third anniversary of 2N Pharma. We Today marks the third anniversary of 2N Pharma. We would like to thank our collaboration partners as well as our employees. #drugdevelopment #ALS #Parkinson #valentineday
    New article! 💙 (See link in bio) The results New article! 💙 (See link in bio) 
 
The results show that in mice with symptoms resembling Parkinson's disease, modulating cellular energy generation can restore both their motor and non-motor functions. Both toxicity-induced and genetic mouse models of Parkinson's disease were used to investigate this.

Congratulations to Dr Michael Sloth Trabjerg MD, 2N Pharma Co-Founder, CSO and Aalborg University Associate Professor Dr John Dirk Vestergaard Nieland, and collaborators on the publication of their newest article in npj Parkinson’s Disease.
 
#article #newarticle #parkinson #parkinsonsdisease #biotech #testing #cellularenergy #parkinsonsdiseaseawareness
#brainhealth #braindisease #newmedicine #turnhopeintoreality #2npharma #mentalhealth #pharma #lifesciences #research #alsawareness #dementia #als #denmark #Aalborg #Nordjylland
    Do you want to learn more about the new medicines Do you want to learn more about the new medicines being developed by 2N Pharma, and the results we have achieved?

Do you have any questions as a patient or relative about what you can do to improve your situation?

👉 Then save the date on April 26, 2023!

Co-founder and CSO Dr. John Vestergaard Nieland, has, in collaboration with his research team, made breakthroughs in the development of new medicines to help improve the life expediency of Parkinson’s, Multiple Sclerosis and Alzheimer’s patients.

In the lecture, John, will discuss how it all fits together. What we have tested for, and how we test it. 

Read more and sign up for the lecture at fuaalborg.dk - "Ny forskning om hjernens sygdomme - Parkinsons sygdom, Multiple Sklerose og Alzheimer"

NB – this lecture is in Danish.

#lecture #aalborguniversity #aalborguniversitet #brainhealth #braindisease #newmedicine #turnhopeintoreality #2npharma #mentalhealth #pharma #lifesciences #research #alsawareness #parkinsonsdisease #dementia #als #denmark #Aalborg #Nordjylland
    Load More... Follow on Instagram

    LinkedIn
    Twitter

    About
    Technology
    Pipeline
    News
    Investors
    Publications
    Contact

    Policies, Terms & Conditions
    Website Terms and Conditions
    Data Privacy Policy
    Cookie Policy
    GDPR Compliance
    2N Pharma ApS
    Novi Science Park, Niels Jernes Vej 10, 9220 Aalborg Ø, Denmark
    BioInnovation Institute, Ole Maaløes Vej 3, 2200 København N, Denmark
    CVR: 41169303 VAT: DK41169303 D-U-N-S: 306192737
    email: info@2npharma.com

    Twitter feed is not available at the moment.